Faron Pharmaceuticals Oy Director/PDMR Shareholding (0505D)

TIDMFARN

RNS Number : 0505D

Faron Pharmaceuticals Oy

21 April 2017

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Director's dealings

TURKU - FINLAND, 21 April 2017 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, announces that it has been notified that Dr Jonathan Knowles, a Non-Executive Director of the Company, acquired 10,000 ordinary shares in Faron at a price of GBP2.65 per share on 12 December 2016, 7,000 ordinary shares in Faron at a price of GBP2.75 per share on 13 December 2016 and 19,000 ordinary shares in Faron at a price of GBP5.50 per share on 31 March 2017. Following these purchases, Dr Knowles holds 46,712 ordinary shares in the Company.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer

[e-mail]

Consilium Strategic Communications

Mary-Jane Elliott, Chris Welsh, Lindsey Neville

Phone: [phone]

E-mail: [e-mail]

Westwicke Partners, IR (US)

Chris Brinzey

Phone: [phone]

E-Mail: [e-mail]

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson, Rebecca Anderson

Phone: [phone]

Panmure Gordon (UK) Limited, Joint Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: [phone]

Whitman Howard Limited, Nominated Broker (UK)

Ranald McGregor-Smith, Francis North

Phone: [phone]

About Faron Pharmaceuticals Ltd

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, cancer immunotherapy and vascular damage. The pipeline is built on Faron's scientific knowledge and control of the endothelial barrier, the membrane of cells lining blood and lymphatic vessels to separate blood content from tissues. The Company's lead candidate Traumakine(R) is in development for the treatment of Acute Respiratory Distress Syndrome ("ARDS"), a rare, severe, life-threatening medical condition characterised by widespread inflammation in the lungs. Traumakine is currently in pan-European (INTEREST) and Japanese pivotal Phase III studies. Additionally, Faron is developing Clevegen(R) a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to convert the immune environment around a tumour from being immune suppressive to immune stimulating. This novel macrophage-directed immuno-oncology approach is called Tumour Immunity Enabling Technology ("TIET") and can be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. New application opportunities related to TIET cover chronic infections and inefficient vaccination. Based in Turku, Finland, Faron Pharmaceuticals is listed on AIM under the ticker 'FARN'. Further information is available at www.faronpharmaceuticals.com

 
 Notification of a Transaction pursuant to Article 
  19(1) of Regulation (EU) No. 596/2014 
----------------------------------------------------------------------- 
 1     Details of the person discharging managerial 
        responsibilities/person closely associated 
----  ----------------------------------------------------------------- 
 a.    Name                                Jonathan Knowles 
                               ---------------------------------------- 
 2     Reason for 
        notification 
----  -----------------------  ---------------------------------------- 
 a.    Position/Status          Director 
----  -----------------------  ---------------------------------------- 
 b.    Initial notification/    Initial Notification 
        Amendment 
----  -----------------------  ---------------------------------------- 
 3     Details of the issuer, emission allowance 
        market participant, auction platform, auctioneer 
        or auction monitor 
      ----------------------------------------------------------------- 
 a.    Name                     Faron Pharmaceuticals Oy 
----  -----------------------  ---------------------------------------- 
 b.    LEI                      7437009H31TO1DC0EB42 
----  -----------------------  ---------------------------------------- 
 4     Details of the transaction(s): section to 
        be repeated for (i) each type of instrument; 
        (ii) each type of transaction; (iii) each 
        date; and (iv) each place where transactions 
        have been conducted 
----  ----------------------------------------------------------------- 
 a.    Description              Ordinary shares 
        of the financial 
        instrument,              ISIN: FI4000153309 
        type of instrument 
 
        Identification 
        Code 
----  -----------------------  ---------------------------------------- 
 b.    Nature of the            Purchase of Ordinary Shares 
        transaction 
----  -----------------------  ---------------------------------------- 
 
 c.    Price(s) and                 Price(s)              Volume(s) 
        volume(s) 
----  -----------------------      --------------------  ---------- 
                                               GBP2.65    7,000 
                                                GBP2.75    10,000 
                                                GBP5.50    19,000 
                                   --------------------  ---------- 
 
       Aggregated 
        information 
 
        - Aggregated 
        Volume 
 
 d.     - Price                 36,000 
----  -----------------------  ---------------------------------------- 
 e.    Date of the              12 December 2016, 13 December 
        transaction              2016 and 31 March 2017 
----  -----------------------  ---------------------------------------- 
 f.    Place of the             London 
        transaction 
----  -----------------------  ---------------------------------------- 
 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHOKDDPABKDPQB

(END) Dow Jones Newswires

April 21, 2017 12:56 ET (16:56 GMT)